Thursday 16 October, 2025
Integrated systems modeling can be defined as the application of mathematics and statistics to understand the transient behavior of biological…
Read moreoral presentation
Dose-Concentration-FACS models for the monoclonal antibody ATM-027, developed for the treatment of Multiple Sclerosis (MS)
Thursday 16 October, 2025
Autoreactive T-cells are implicated in the pathogenesis of several autoimmune conditions e.g. rheumatoid arthritis, psoriasis and multiple sclerosis. A humanized…
Read moreA mechanism based population PK/PD model of UK-279,276 in healthy volunteers and patients
Thursday 16 October, 2025
UK-279,276 is a recombinant glycoprotein, derived from canine hookworm, and is an antagonist of the adhesion molecule CD11b/CD18. It is…
Read moreDealing With Missing Data in Longitudinal Studies Through Modeling
Thursday 16 October, 2025
A standard clinical trial assigns treatments A, observes outcomes Y, and, generically, uses the disparity between the goodness of fit…
Read moreGraphical Models and Missing Data
Thursday 16 October, 2025
Missing data are often ‘non-ignorable’, for example, assayed concentrations that fall below the limit of quantification (LOQ). In this talk…
Read moreAuckland Bones and Summer Sun
Thursday 16 October, 2025
Osteoporosis is common in post-menopausal women. A variety of drug treatments have been approved for treatment of osteoporosis and the…
Read moreInfluence of LOQ on the pharmacokinetics parameters after an IV bolus dose
Thursday 16 October, 2025
This study aimed to evaluate the influence of the limit of quantification (LOQ) on the estimation of pharmacokinetics parameters after…
Read moreThe natural progression of P.falciparum malaria:- Investigation of a historical cohort of syphilis patients treated with malariatherapy.
Thursday 16 October, 2025
A retrospective analysis was performed of parasite count data recorded from the first seven days of blood or mosquito transmitted…
Read morePopulation PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug.
Thursday 16 October, 2025
In 2 phase 1 studies, neutropenia was identified as the major dose limiting toxicity of a new anticancer drug. We…
Read moreBayesian Optimal Design Applied to Mixed Effect Pharmacokinetic Models
Thursday 16 October, 2025
Research into design issues associated with experiments resulting in data analysed using mixed effect models have become prominent in recent…
Read more